Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic graft-versus-host disease.

Mitchell E Horwitz1, Keith M Sullivan

  • 1Division of Cellular Therapy, Duke University Medical Center, 2400 Pratt Street DUMC 3961, Durham, NC 27710, USA. mitchell.horwitz@duke.edu

Blood Reviews
|January 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reflections Turns Three Years Old.

Transplantation and cellular therapy·2026
Same author

Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.

Bone marrow transplantation·2026
Same author

Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.

Bone marrow transplantation·2026
Same author

Getting it Right: Standards in Marrow Transplant and Cellular Therapy.

Transplantation and cellular therapy·2026
Same author

Academic Career Success: Love, Family and Research Skills.

Transplantation and cellular therapy·2026
Same author

Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel.

British journal of haematology·2026

Chronic graft-versus-host disease (GVHD) affects half of allogeneic stem cell transplant patients. Early treatment improves survival, while severe cases have a poor prognosis, often due to infections.

Area of Science:

  • Medicine
  • Immunology
  • Hematology

Background:

  • Chronic graft-versus-host disease (GVHD) is a significant late complication following allogeneic stem cell transplantation.
  • It affects approximately 50% of transplant recipients, manifesting at least 100 days post-transplant.
  • Increased use of peripheral blood stem cells and older recipient age contribute to higher chronic GVHD incidence.

Purpose of the Study:

  • To review the current understanding of chronic GVHD, including its pathophysiology, clinical manifestations, and treatment strategies.
  • To highlight the impact of chronic GVHD on patient survival and quality of life.

Main Methods:

  • Literature review of chronic GVHD, focusing on incidence, risk factors, affected organs, and treatment outcomes.
  • Analysis of standard treatment regimens and their efficacy.

Related Experiment Videos

Main Results:

  • Chronic GVHD commonly affects the skin, liver, eyes, and mouth, leading to a severely immunocompromised state.
  • Standard treatment involves cyclosporine and prednisone, with an alternating day regimen showing improved survival and reduced adverse events.
  • Topical therapy is recommended for mild cases.
  • Ten-year survival is approximately 80% for mild chronic GVHD but less than 5% for severe cases.

Conclusions:

  • Chronic GVHD poses a significant challenge in allogeneic stem cell transplantation, with severe forms having a dismal prognosis.
  • Effective management, including early intervention and optimized treatment regimens, is crucial for improving patient outcomes.
  • Infectious complications remain a primary cause of mortality in severe chronic GVHD.